12 results about "Vascular obstruction" patented technology

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

The disclosed technology relates to a catheter configured to reduce microvascular obstruction (MVO) in myocardial tissue at risk due to an acute myocardial infarction (AMI). The catheter comprises a catheter shaft that is configured to be inserted into a heart of a patient. A channel is arranged in the heart and is configured to deliver blood from a first location in the heart to a second location in the heart. A pressure sensor is configured to monitor pressure at the second location to ensure controlled delivery of blood from the first location to the second location. The catheter device is operable to reduce the amount of tissue actually comprising MVO by approximately 20% compared to untreated regions.

To provide a clot retrieval device.SOLUTION: The disclosed technology includes a clot retrieval device configured to retrieve a clot from a blood vessel and having a constrained delivery configuration and a clot engaging configuration. The device includes a first expandable framework having a first plurality of struts that form a first body and a second expandable framework having a second plurality of struts that form a second body, upon the clot retrieval device transitioning from the constrained delivery configuration to the clot engaging configuration. In the clot engaging configuration, the first body can be configured to move from a first position to a second position in relation to the second body. Upon moving from the first position to the second position, the clot retrieval device can pinch the clot between the first body and the second body.SELECTED DRAWING: Figure 1A

Methods and systems are provided for diagnosis and / or treatment of microvascular dysfunction, such as microvascular obstruction (MVO) by injecting volumetric flows into a vessel using an infusion system to arrest or reverse native antegrade flow, such that an equipoise value of volumetric flow rate and corresponding pressure may be determined, which in turn enables calculation of MVO, absolute hydrodynamic resistance, fractional flow reserve, coronary flow reserve, and other physiologic parameters in real-time or near real time.

Sickle cell disease (SCD) is a single gene disorder characterized by mutant hemoglobin-S (HbS) and chronic intravascular haemolysis. Painful vaso-occlusive crises (VOC) are typical of SCD and often associated to a further rise in hemolysis. VOC is the clinically painful form of vaso-occlusion, that is due to the aggregation of red blood cells in the capillaries and venules. Such event is promoted or aggravated by adhesion of polymorphonuclear neutrophils (PMNs) to red blood cells and the endothelium leading to tissue ischemia, inflammation and imperfect repair. Repeated vaso-occlusion and PMNs interactions with the vascular endothelium are thought to promote microvascular injuries in SCD patients. The inventors tested the effect of pharmacological inhibition of TREM-1 with LR12 peptide in two experimental vaso-occlusive crisis models. Additional validation of TREM-1 involvement in vaso-occlusion was verified using mice with sickle cell disease and Trem-1 gene deficiency. In particular, the inventors showed that TREM-1 inhibition is particular suitable for limiting the severity of vaso-occlusions. The results obtained by the inventors also suggest that plasmatic concentration of sTREM-1 could be a reliable biomarker for predicting vaso-occlusions and / or SCD-associated organ dysfunction and end-organ damage.

The invention relates to the technical field of medical image processing and analysis, in particular to a cardiovascular image analysis system which comprises the steps that image collection is conducted on a target blood vessel through angiocardiography equipment, a time sequence image sequence is formed, and the contrast agent injection time and the heart rate are synchronously recorded; calculating a pixel displacement field based on a time sequence image sequence, obtaining displacement through local pixel gray matching, forming a motion vector containing direction and distance, indirectly quantifying the blood flow velocity, then converting into a blood flow topological graph, coding the flow velocity by vector arrows and colors, and forming a continuous path through streamline interpolation; the vorticity is calculated through the spatial change rate of the flow velocity component, a vortex region is calculated and defined according to the vorticity, and a vortex breaking point is positioned in the region by using an extreme point detection algorithm; and constructing a narrow correlation index based on the vortex breaking point density and the blood flow breaking line length, and judging the blood vessel obstruction degree according to an index interval. Based on the correlation index, objective evaluation criteria are provided for stenosis of different degrees.

The invention discloses a vascular obstruction micronization system based on ultrafast laser, which comprises a first scanning module, an optical focusing module and a second scanning module, and is characterized in that the first scanning module is used for moving the optical focusing module to a specified position along a preset three-dimensional moving track; the optical focusing module is arranged at the tail end of the first scanning module and used for focusing the laser to a specified position and triggering a mechanical pulverization cavitation effect at a focal point so as to micronize vascular obstructions, and the second scanning module is arranged at the tail end of the first scanning module and used for controlling the focal point of the laser to scan in a specified area. Through multi-stage scanning and synchronous positioning, the risk of trauma and complications can be effectively reduced.

The application relates to an analysis method, system and device of a fundus image. The method comprises the following steps: acquiring a fundus image; classifying the fundus image based on coarse-grained features to obtain a first classification result, wherein the first classification result comprises retinal vein obstruction, retinal artery obstruction and a normal sample; classifying the fundus image with the first classification result of retinal artery obstruction based on fine-grained features to obtain retinal branch artery obstruction and central retinal artery obstruction classification results, or classifying the fundus image with the first classification result of retinal vein obstruction based on fine-grained features to obtain retinal branch vein obstruction and central retinal vein obstruction classification results. The application aims to realize classification and prediction of retinal vascular obstruction by fusing coarse-grained features and fine-grained features through a constructed fundus image hierarchical model, and to explore the capability and potential application value of the fundus image analysis.

The present invention provides an application of a sardine peptide composition in a drug for treating allergic rhinitis. The sardine peptide composition is a mixture of dipeptide to pentapeptide of sardine. The biological activities of various peptide fragments are synergistic. The sardine medicine composition has the effects of inhibiting nasal cavity inflammation attack and preventing nasal cavity capillary obstruction, and can also improve rhinocnesmus, sneezing, rhinorrhea and nasal obstruction caused by allergic rhinitis, as well as various symptoms accompanied with itching of palate, throat, ears and eyes, red and swollen eyes and water secretions. Meanwhile, the sardine peptide composition has no irritation to patients with nasal mucous membrane sensitivity, systemic side effects such as local side effects and drowsiness are not observed, and the sardine peptide composition has excellent effectiveness and safety.

The application discloses a catheter assembly capable of removing vascular obstruction plaque, which comprises a balloon catheter, the balloon catheter comprises an inner catheter and a balloon arranged on the inner catheter and capable of being inflated, the catheter assembly further comprises a first catheter capable of being sleeved on the balloon catheter in a relatively sliding mode, a second catheter capable of being sleeved on the first catheter in a relatively sliding mode, and a filter screen sleeve with a meshed peripheral wall, the filter screen sleeve is capable of being sleeved on the first sleeve in a relatively sliding mode, a front end of the filter screen sleeve is fixedly connected to a front part of the first catheter, and a rear end of the filter screen sleeve is fixedly connected to a front part of the second catheter. After removing the calcified plaque obstructing in the blood vessel, the broken calcified plaque can be removed from the blood vessel by using the catheter assembly, so that the risk caused by the calcified plaque remaining in the blood vessel and flowing with the blood is avoided. The catheter assembly has simple structure and is convenient to operate.

The disclosed technology relates to methods of preventing or limiting effects of heart failure in a human patient that has sustained acute myocardial infarction. The method includes determining that the patient is exhibiting acute myocardial infarction, inserting a transvalvular pump at least partially into a heart of the patient, and operating the transvalvular pump to cause blood to flow at a rate of at least 2.5 L / min for at least a support period. The method further includes performing a reperfusion of the patient's heart to restore blood flow to the heart after at least the support period has ended and reducing the amount of tissue actually comprising microvascular obstruction (MVO) of tissue that is at risk of MVO by approximately 20%.